Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN)

References

• Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257:7847-51; PMID: 7085651
   PubMed Web of Science ®Google Scholar
• Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012; 11:937-57; PMID: 23197040; http://dx.doi.org/10.1038/nrd3871
   PubMed Web of Science ®Google Scholar
• Reyland ME. Protein kinase C isoforms: Multi-functional regulators of cell life and death. Front Biosci 2009; 14:2386-99; http://dx.doi.org/10.2741/3385
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999; 18:2221-30; PMID: 10327068; http://dx.doi.org/10.1038/sj.onc.1202527
   PubMed Web of Science ®Google Scholar
• Suzuma K, Takahara N, Suzuma I, Isshiki K, Ueki K, Leitges M, Aiello LP, King GL. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 2002; 99:721-6; PMID: 11805327; http://dx.doi.org/10.1073/pnas.022644499
   PubMed Web of Science ®Google Scholar
• Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46:1473-80; http://dx.doi.org/10.2337/diab.46.9.1473
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999; 59:4413-8; PMID: 10485491
   PubMed Web of Science ®Google Scholar
• Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol 2002; 49:69-77; PMID: 11855754; http://dx.doi.org/10.1007/s00280-001-0386-2
   PubMed Web of Science ®Google Scholar
• Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzenburger UM, Sahm F, et al. Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2013; 110:14735-40; PMID: 23959874; http://dx.doi.org/10.1073/pnas.1302569110
   PubMed Web of Science ®Google Scholar
• Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999; 145:699-711; PMID: 10330400; http://dx.doi.org/10.1083/jcb.145.4.699
   PubMed Web of Science ®Google Scholar
• Murray NR, Weems J, Braun U, Leitges M, Fields AP. Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression. Cancer Res 2009; 69:656-62; PMID: 19147581; http://dx.doi.org/10.1158/0008-5472.CAN-08-3001
   PubMed Web of Science ®Google Scholar
• Sauma S, Yan Z, Ohno S, Friedman E. Protein kinase C beta 1 and protein kinase C beta 2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells. Cell Growth Differ 1996; 7:587-94.
   PubMedGoogle Scholar
• Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 2003; 13:1857-9; PMID: 12749884 http://dx.doi.org/10.1016/S0960-894X(03)00286-5
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65:7462-9; PMID: 16103100; http://dx.doi.org/10.1158/0008-5472.CAN-05-0071
   PubMed Web of Science ®Google Scholar
• Dumstorf CA, Konicek BW, McNulty AM, Parsons SH, Furic L, Sonenberg N, Graff JR. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther 2010; 9:3158-63; PMID: 20971826; http://dx.doi.org/10.1158/1535-7163.MCT-10-0413
   PubMed Web of Science ®Google Scholar
• Glimelius B, Lahn M, Gawande S, Cleverly A, Darstein C, Musib L, Liu Y, Spindler KL, Frödin JE, Berglund A, et al. A window of opportunity phase II study of enzastaurin in chemonaive pat-ients with asymptomatic metastatic colorectal cancer. Ann Oncol 2010; 21:1020-6; PMID: 19901015; http://dx.doi.org/10.1093/annonc/mdp521
   PubMed Web of Science ®Google Scholar
• Wolff RA, Fuchs M, Di Bartolomeo M, Hossain AM, Stoffregen C, Nicol S, Heinemann V. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. Cancer 2012; 118:4132-8; PMID: 22213153; http://dx.doi.org/10.1002/cncr.26692
   PubMed Web of Science ®Google Scholar
• Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24:4092-9; PMID: 16943527; http://dx.doi.org/10.1200/JCO.2005.05.3447
   PubMed Web of Science ®Google Scholar
• Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38:1043-8; PMID: 16921376; http://dx.doi.org/10.1038/ng1861
   PubMed Web of Science ®Google Scholar
• Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008; 57:941-50; PMID: 18364437; http://dx.doi.org/10.1136/gut.2007.135004
   PubMed Web of Science ®Google Scholar
• Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009; 106:7131-6
   Google Scholar
• Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011; 71:1858-70; PMID: 21363922; http://dx.doi.org/10.1158/0008-5472.CAN-10-3604
   PubMed Web of Science ®Google Scholar
• Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M, Praz F. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63:5738-44; PMID: 14522894
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330-7; PMID: 22810696; http://dx.doi.org/10.1038/nature11252
   PubMed Web of Science ®Google Scholar
• Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 1999; 97:99-109; PMID: 10199406; http://dx.doi.org/10.1016/S0092-8674(00)80718-7
   PubMed Web of Science ®Google Scholar
• Hans F, Dimitrov S. Histone H3 phosphorylation and cell division. Oncogene 2001; 20:3021-7; PMID: 11420717; http://dx.doi.org/10.1038/sj.onc.1204326
   PubMed Web of Science ®Google Scholar
• Escargueil AE, Larsen AK. Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A. Biochem J 2007; 403:235-42; PMID: 17212588; http://dx.doi.org/10.1042/BJ20061460
   PubMed Web of Science ®Google Scholar
• Li W, Lan Z, Wu H, Wu S, Meadows J, Chen J, Zhu V, Dai W. BUBR1 phosphorylation is regulated during mitotic checkpoint activation. Cell Growth Differ 1999; 10:769-75; PMID: 10593653
   PubMedGoogle Scholar
• Chan GK, Jablonski SA, Sudakin V, Hittle JC, Yen TJ. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 1999; 146:941-54; PMID: 10477750; http://dx.doi.org/10.1083/jcb.146.5.941
   PubMed Web of Science ®Google Scholar
• Enomoto M, Goto H, Tomono Y, Kasahara K, Tsujimura K, Kiyono T, Inagaki M. Novel positive feedback loop between Cdk1 and Chk1 in the nucleus during G2/M transition. J Biol Chem 2009; 284:34223-30; PMID: 19837665; http://dx.doi.org/10.1074/jbc.C109.051540
   PubMed Web of Science ®Google Scholar
• Ghadimi BM, Sackett DL, Difilippantonio MJ, Schröck E, Neumann T, Jauho A, Auer G, Ried T. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 2000; 27:183-90; PMID: 10612807; http://dx.doi.org/10.1002/(SICI)1098-2264(200002)27:2%3c183::AID-GCC10%3e3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385-92; PMID: 21527953; http://dx.doi.org/10.1038/nrm3115
   PubMed Web of Science ®Google Scholar
• Colombo R, Moll J. Targeting aneuploid cancer cells. Expert Opin Ther Targets 2011; 15:595-608; PMID: 21314491
   PubMed Web of Science ®Google Scholar
• Silverman-Gavrila R, Silverman-Gavrila L, Bendeck MP. Cell division fidelity is altered during the vascular response to injury: its novel role in atherosclerosis progression. Am J Pathol 2013; 182:628-39; PMID: 23260773; http://dx.doi.org/10.1016/j.ajpath.2012.11.007
   PubMed Web of Science ®Google Scholar
• Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009; 175:2657-67; PMID: 19875502; http://dx.doi.org/10.2353/ajpath.2009.090202
   PubMed Web of Science ®Google Scholar
• Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T, Yamamoto K, Kondoh M, et al. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 2012; 180:1294-307; PMID: 22245217; http://dx.doi.org/10.1016/j.ajpath.2011.11.035
   PubMed Web of Science ®Google Scholar
• Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009; 106:8671-6
   Google Scholar
• Bracht K, Nicholls AM, Liu Y, Bodmer WF. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer 2010; 103:340-6; PMID: 20606684; http://dx.doi.org/10.1038/sj.bjc.6605780
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103:863-75; PMID: 21597022; http://dx.doi.org/10.1093/jnci/djr153
   PubMed Web of Science ®Google Scholar
• Zimmerman WC, Sillibourne J, Rosa J, Doxsey SJ. Mitosis-specific anchoring of gamma tubulin complexes by pericentrin controls spindle organization and -mitotic entry. Mol Biol Cell 2004; 15:3642-57; PMID: 15146056; http://dx.doi.org/10.1091/mbc.E03-11-0796
   PubMed Web of Science ®Google Scholar
• Chen D, Purohit A, Halilovic E, Doxsey SJ, Newton AC. Centrosomal anchoring of protein kinase C βII by pericentrin controls microtubule organization, spindle function, and cytokinesis. J Biol Chem 2004; 279:4829-39; PMID: 14594954; http://dx.doi.org/10.1074/jbc.M311196200
   PubMed Web of Science ®Google Scholar
• Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM, Mochly-Rosen D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res 2008; 68:6831-9; PMID: 18701509; http://dx.doi.org/10.1158/0008-5472.CAN-07-6195
   PubMed Web of Science ®Google Scholar
• Bekier ME, Fischbach R, Lee J, Taylor WR. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther 2009; 8:1646-54; PMID: 19509263; http://dx.doi.org/10.1158/1535-7163.MCT-08-1084
   PubMed Web of Science ®Google Scholar
• Kimura M, Yoshioka T, Saio M, Banno Y, Nagaoka H, Okano Y. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis 2013; 4:e603; PMID: AMBIGUOUS
   PubMed Web of Science ®Google Scholar
• Giovinazzi S, Bellapu D, Morozov VM, Ishov AM. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cycle 2013; 12:2598-607; PMID: 23907120; http://dx.doi.org/10.4161/cc.25591
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007; 6:70-4; PMID: 17245109; http://dx.doi.org/10.4161/cc.6.1.3682
   PubMed Web of Science ®Google Scholar
• Hemström TH, Sandström M, Zhivotovsky B. Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells. Int J Cancer 2006; 119:1028-38; PMID: 16570272; http://dx.doi.org/10.1002/ijc.21927
   PubMed Web of Science ®Google Scholar
• Skladanowski A, Bozko P, Sabisz M, Larsen AK. Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 2007; 6:2268-75; PMID: 17890906; http://dx.doi.org/10.4161/cc.6.18.4705
   PubMed Web of Science ®Google Scholar
• Mésange P, Poindessous V, Sabbah M, Escargueil AE, de Gramont A, Larsen AK. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 2014; 5:4709-21; PMID: 25015210
   Google Scholar
• Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007; 6:2344-7; PMID: 17700066; http://dx.doi.org/10.4161/cc.6.19.4754
   PubMed Web of Science ®Google Scholar
• Larsen AK, Escargueil AE, Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 2003; 5:295-300; PMID: 14593724
   PubMedGoogle Scholar
• Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011; 131:80-90; PMID: 21439312; http://dx.doi.org/10.1016/j.pharmthera.2011.03.012
   PubMed Web of Science ®Google Scholar
• Petitprez A, Larsen AK. Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. Curr Pharm Des 2013; 19:958-64; PMID: 22973964; http://dx.doi.org/10.2174/138161213804547204
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-67; PMID: 22267462
   PubMed Web of Science ®Google Scholar
• Roschke AV, Kirsch IR. Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability. Cell Cycle 2005; 4:679-82; PMID: 15846096; http://dx.doi.org/10.4161/cc.4.5.1687
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med 2003; 9:307-12; PMID: 12900218; http://dx.doi.org/10.1016/S1471-4914(03)00111-4
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307-12; PMID: 18487952; http://dx.doi.org/10.4161/cc.7.10.6250
   PubMed Web of Science ®Google Scholar
• Li H, Yang BB. MicroRNA in drug resistance. Oncoscience 2014; 1(1):3-4.
   PubMedGoogle Scholar
• Ragusa M, Statello L, Maugeri M, Barbagallo C, Passanisi R, Alhamdani MS, Li Destri G, Cappellani A, Barbagallo D, Scalia M, et al. Highly skewed distribution of microRNA. Oncoscience 2014; 1(2):132-57.
   PubMedGoogle Scholar
• Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget 2012; 3:1711-24; PMID: 23565531
   PubMed Web of Science ®Google Scholar
• Poindessous V, Koeppel F, Raymond E, Comisso M, Waters SJ, Larsen AK. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res 2003; 9:2817-25; PMID: 12855662
   PubMed Web of Science ®Google Scholar
• Skladanowski A, Côme MG, Sabisz M, Escargueil AE, Larsen AK. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents. Mol Pharmacol 2005; 68:625-34; PMID: 15942022
   PubMed Web of Science ®Google Scholar
• Escargueil AE, Poindessous V, Soares DG, Sarasin A, Cook PR, Larsen AK. Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells. J Cel l Sci 2008; 121:1275-83; http://dx.doi.org/10.1242/jcs.023259
   PubMed Web of Science ®Google Scholar
• Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007; 2:1084-104; PMID: 17546000; http://dx.doi.org/10.1038/nprot.2007.77
   PubMed Web of Science ®Google Scholar
• Hovhannisyan G, Aroutiounian R, Glei M. Butyrate reduces the frequency of micronuclei in human colon carcinoma cells in vitro. Toxicol In Vitro 2009; 23:1028-33; PMID: 19539745; http://dx.doi.org/10.1016/j.tiv.2009.06.011
   PubMed Web of Science ®Google Scholar